NCT06532344进行中（未招募）1 期
An Open-label, Uncontrolled Study of ONO-7913 and ONO-4538 in Combination With Modified FOLFIRINOX Therapy, the Standard of Care, as First-line Treatment in Patients With Metastatic Pancreatic Cancer
适应症
干预措施
相关药物
试验速览
- 阶段
- 1 期
- 状态
- 进行中（未招募）
- 入组人数
- 32
- 试验地点
- 9
- 主要终点
- Adverse event(AE)
研究概览
简要总结
To investigate the tolerability and safety of ONO-7913 and ONO-4538 used in combination with modified FOLFIRINOX (mFFX therapy), the standard of care, as first-line treatment in patients with metastatic pancreatic cancer.
研究设计
- 研究类型
- Interventional
- 分配方式
- Na
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 20 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Untreated metastatic pancreatic cancer
- •Life expectancy of at least 3 months
- •Patients with ECOG performance status 0 or 1
排除标准
- •Patients with severe complication
- •Patients with multiple primary cancers
研究组 & 干预措施
ONO-7913+ONO-4538+mFFX
Experimental
干预措施: ONO-7913 (Drug)
ONO-7913+ONO-4538+mFFX
Experimental
干预措施: ONO-4538 (Drug)
ONO-7913+ONO-4538+mFFX
Experimental
干预措施: Oxaliplatin (Drug)
ONO-7913+ONO-4538+mFFX
Experimental
干预措施: Levofolinate (Drug)
ONO-7913+ONO-4538+mFFX
Experimental
干预措施: Irinotecan (Drug)
ONO-7913+ONO-4538+mFFX
Experimental
干预措施: Fluorouracil (Drug)
结局指标
主要结局
Adverse event(AE)
时间窗: UP to 30 days after the last dose
Dose-limiting toxicities（DLT）
时间窗: 28 days
次要结局
- Pharmacokinetics（serum concentration of ONO-4538）(Through study completion, an average of 6 months)
- Pharmacokinetics（serum concentration of ONO-7913）(Through study completion, an average of 6 months)
- Overall response rate (ORR)(Through study completion, an average of 6 months)
- Disease control rate (DCR)(Through study completion, an average of 6 months)
- Best overall response (BOR)(Through study completion, an average of 6 months)
- Duration of response (DOR)(Through study completion, an average of 6 months)
- Time to response (TTR)(Through study completion, an average of 6 months)
- Overall survival (OS)(Through study completion, an average of 6 months)
- Progression-free survival (PFS)(Through study completion, an average of 6 months)
- Percentage of change in the sum of tumor diameters of target lesions(Through study completion, an average of 6 months)
- Maximum percentage of change in the sum of tumor diameters of target lesions(Through study completion, an average of 6 months)
- Changes in tumor markers (CEA and CA19-9)(Through study completion, an average of 6 months)
研究者
研究点 (9)
Loading locations...
相似试验
进行中（未招募）
1 期
The Study of ONO-7913, ONO-4538 and the Standard of Care as First-line Treatment in Patients Colorectal CancerUnresectable Colorectal CancerNCT06540261Ono Pharmaceutical Co. Ltd65
已完成
1 期
Phase 1 Study of ONO-7475 With and Without ONO-4538 in Subjects Advanced or Metastatic Solid TumorsAdvanced or Metastatic Solid TumorsNCT03730337Ono Pharmaceutical Co. Ltd24
进行中（未招募）
1 期
Study of ONO-4578 and XELOX/FOLFOX Plus Bevacizumab in Colorectal CancerColorectal CancerNCT06547385Ono Pharmaceutical Co. Ltd40
进行中（未招募）
1 期
An Open-label, Uncontrolled Study of ONO-4578 and ONO-4538 in Combination With Standard-of-care Docetaxel and Ramucirumab as Second-line Therapy in Patients With Advanced or Recurrent Non-small Cell Lung CancerNon-small Cell Lung CancerNCT06542731Ono Pharmaceutical Co. Ltd42
进行中（未招募）
1 期
A PhaseⅠStudy of ONO-7475 in Combination With ONO-4538 and Gemcitabine Plus Nab-paclitaxel (GnP), the Standard of Care, and ONO-7475 in Combination With GnP in Patients With Pancreatic CancerMetastatic Pancreatic CancerNCT06532331Ono Pharmaceutical Co. Ltd87